menu
    • menu
    [{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"LTI-01","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Lung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lung Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lung Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Aileron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Lung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Lung Therapeutics \/ Aileron Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Lung Therapeutics \/ Aileron Therapeutics"},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Lung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Lung Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lung Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Lung Therapeutics

    Menu

    Lung Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lung Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Lung Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTI-03

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Aileron Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Announces Acquisition of Lung Therapeutics

                            Details : The acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF).

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : LTI-03

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Aileron Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lung Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Lung Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTI-03

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lung Therapeutics Announces Successful Completion of Phase 1a Clinical Trial of LTI-03 in Healthy Volunteers

                            Details : The phase 1a clinical trial assessed ascending doses of LTI-03,, a Caveolin-1-related peptide in healthy normal volunteers. LTI-03 dose levels from 2.5 mg to 10 mg appeared to be safe and well tolerated with no reports of discontinuations or serious adve...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 22, 2022

                            Lead Product(s) : LTI-03

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lung Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Lung Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTI-01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Taiho and Lung Therapeutics Enter into an Exclusive License Agreement in Japan for LTI-01, Treatment for Locul...

                            Details : Under the terms of the agreement, Taiho will obtain the rights for the development and commercialization of LTI-01 in Japan. Lung Tx will receive an upfront payment, milestone, and royalty payments based on product sales.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            November 12, 2020

                            Lead Product(s) : LTI-01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.